Zacks Research Analysts Lower Earnings Estimates for STERIS

STERIS plc (NYSE:STE) – Analysts at Zacks Research reduced their Q4 2025 earnings estimates for shares of STERIS in a research note issued to investors on Tuesday, February 25th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will earn $2.59 per share for the quarter, down from their prior estimate of $2.60. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q3 2026 earnings at $2.52 EPS, Q4 2026 earnings at $2.71 EPS and FY2026 earnings at $9.90 EPS.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts’ consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%.

STE has been the subject of a number of other reports. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler increased their price objective on shares of STERIS from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Stephens restated an “overweight” rating and set a $240.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $258.75.

STERIS Price Performance

Shares of NYSE STE opened at $219.23 on Friday. The firm has a market cap of $21.54 billion, a PE ratio of 46.54 and a beta of 0.84. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS has a 1-year low of $197.82 and a 1-year high of $248.24. The company has a fifty day moving average price of $214.99 and a 200 day moving average price of $223.01.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be issued a $0.57 dividend. The ex-dividend date is Thursday, February 20th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 1.04%. STERIS’s payout ratio is 48.41%.

Institutional Investors Weigh In On STERIS

A number of institutional investors and hedge funds have recently modified their holdings of the company. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of STERIS in the 4th quarter valued at about $10,623,000. Mackenzie Financial Corp raised its holdings in shares of STERIS by 12.9% in the 4th quarter. Mackenzie Financial Corp now owns 9,399 shares of the medical equipment provider’s stock valued at $1,932,000 after purchasing an additional 1,074 shares during the period. Forum Financial Management LP raised its holdings in shares of STERIS by 7.1% in the 4th quarter. Forum Financial Management LP now owns 1,184 shares of the medical equipment provider’s stock valued at $243,000 after purchasing an additional 78 shares during the period. GF Fund Management CO. LTD. bought a new stake in shares of STERIS in the 4th quarter valued at about $509,000. Finally, Public Employees Retirement System of Ohio raised its holdings in shares of STERIS by 5.2% in the 4th quarter. Public Employees Retirement System of Ohio now owns 46,200 shares of the medical equipment provider’s stock valued at $9,497,000 after purchasing an additional 2,272 shares during the period. 94.69% of the stock is owned by institutional investors.

About STERIS

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.